Venus Medtech (Hangzhou) Inc. (Stock Code: 2500) published a circular on November 12, 2025, outlining a major transaction involving the disposal of certain in-progress property and associated land use rights in Hangzhou, the People’s Republic of China.

According to the circular, the transaction involves construction in progress on two land parcels ([2021]-22 Hangzhenggong and [2021]-23 Hangzhenggong) at Binjiang District, Hangzhou, together with their land use rights. The total consideration for the disposal is reported at RMB374,563,969. Payments will be settled in several installments and allocated toward repaying outstanding bank loans of approximately RMB265 million and covering various fees due to service providers involved in the project, with the remaining funds designated for general working capital.

The circular indicates that this transaction constitutes a major transaction under the Listing Rules. The company will convene an extraordinary general meeting on November 28, 2025, at 10:00 a.m. in Hangzhou. Shareholders whose names appear on the register of members by the specified date will be eligible to vote on approving the disposal and related matters. Shareholders are advised to review the published circular for details on registration and proxy arrangements.